STOCK TITAN
  1. Home
  2. News
  3. ARQT

Arcutis Biotherapeutics, Inc. - ARQT STOCK NEWS

Welcome to our dedicated page for Arcutis Biotherapeutics news (Ticker: ARQT), a resource for investors and traders seeking the latest updates and insights on Arcutis Biotherapeutics stock.

Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) is a commercial-stage medical dermatology company based in Westlake Village, California, specializing in developing and commercializing treatments for dermatological diseases. Founded in 2016, Arcutis leverages recent advances in immunology and inflammation to create differentiated therapies targeting immune-mediated dermatological conditions.

Arcutis' lead product, ZORYVE (roflumilast) cream, is a topical treatment for plaque psoriasis and atopic dermatitis. The company has recently launched ZORYVE topical foam for seborrheic dermatitis and scalp psoriasis. Both formulations utilize roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor that has shown significant improvement in clinical trials.

Arcutis is also advancing its pipeline with ARQ-252, a selective topical small molecule inhibitor of janus kinase type 1 for hand eczema, and ARQ-255 for alopecia areata. The company champions meaningful innovation to address the urgent needs of patients living with chronic, immune-mediated skin conditions, aiming to improve treatment options and patient outcomes.

In recent developments, Arcutis has been actively participating in industry conferences, securing strategic collaborations, and expanding its workforce. The company's financial health is robust, with a strong cash position bolstered by a recent public offering and a strategic licensing agreement in Japan. Arcutis continues to focus on long-term growth and innovation, with multiple ongoing clinical programs targeting various inflammatory dermatological conditions.

For more information, visit www.arcutis.com or follow Arcutis on LinkedIn, Facebook, Instagram, and X.

News

Arcutis Presents Late-Breaking Data From INTEGUMENT-PED Phase 3 Trial of Roflumilast Cream 0.05% in Atopic Dermatitis in Children Ages 2 to 5 at the American Academy of Dermatology Annual Meeting

Rhea-AI Summary
Arcutis Biotherapeutics, Inc. presented positive results from the INTEGUMENT-PED Phase 3 study of roflumilast cream 0.05% for children with atopic dermatitis at the AAD annual meeting. The cream met primary and secondary endpoints, showing significant improvement in EASI-75, vIGA-AD, and itch reduction. Roflumilast cream demonstrated consistent efficacy, safety, and tolerability in children aged 2 to 5, with potential for approval as a well-tolerated treatment option.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.96%
Tags
clinical trial
-
News

New Research Reveals Genomic Profile of Seborrheic Dermatitis and Answers Key Questions on Immune Response and Skin Barrier Dysfunction

Rhea-AI Summary
Arcutis Biotherapeutics, Inc. highlights new research revealing the gene expression profile of seborrheic dermatitis, a unique inflammatory skin disease with its own molecular signature. The study suggests distinct skin barrier disruption in seborrheic dermatitis, providing key insights into the immune response of the condition.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.96%
Tags
none
-
News

Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary
Arcutis Biotherapeutics, Inc. grants 12,000 restricted stock units to new employees under the 2022 Inducement Plan. The units vest over four years, subject to continuous employment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.22%
Tags
none
News

Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (ARQT) announced the closing of a public offering, selling 18,157,895 shares at $9.50 per share, raising approximately $172.5 million. The underwriters exercised their option to purchase additional shares, leading to a total gross proceeds before expenses. Various investment firms acted as lead managers for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.46%
Tags
offering
-
News

Arcutis Announces Acceptance of Late Breaking Abstract in Atopic Dermatitis Among Five New Topical Roflumilast Data Being Presented at the American Academy of Dermatology Annual Meeting

Rhea-AI Summary
Arcutis Biotherapeutics, Inc. to present new data at the 2024 AAD annual meeting on roflumilast cream and foam for dermatological conditions. The company showcases positive results from Phase 3 trials in atopic dermatitis, psoriasis, and seborrheic dermatitis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.97%
Tags
none
-
News

Arcutis to Present at the TD Cowen 44th Annual Health Care Conference

Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (ARQT) will participate in the TD Cowen 44th Annual Health Care Conference with a Fireside Chat on March 4, 2024, at 2:10 pm ET. The webcast can be accessed on the company's website, with a replay available for 180 days post-conference.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
14.49%
Tags
conferences
News

Arcutis Announces Pricing of $150 Million Public Offering

Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (ARQT) announced the pricing of its underwritten public offering of common stock, selling 15,789,474 shares at $9.50 per share. The gross proceeds are expected to be approximately $150.0 million. The offering is expected to close on March 4, 2024, with the intention to fund commercialization, development, and approval of various programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
offering
-
News

Arcutis Announces Proposed Public Offering

Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (ARQT) announces a public offering of $150.0 million of common stock and pre-funded warrants. The underwritten offering includes an option for additional shares. Morgan Stanley, TD Cowen, and Guggenheim Securities are the lead bookrunning managers. The offering is subject to market conditions and regulatory approvals.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
offering
-
News

Arcutis and Sato Announce Strategic Collaboration and Licensing Agreement for Topical Roflumilast in Japan

Rhea-AI Summary
Arcutis Biotherapeutics, Inc. partners with Sato Pharmaceutical Co., Ltd. for the development and commercialization of topical roflumilast in Japan, receiving a $25 million upfront payment and potential milestone payments totaling $40 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.25%
Tags
none
News

Arcutis Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Rhea-AI Summary
Arcutis Biotherapeutics, Inc. (ARQT) reported Q4 net product revenues of $13.5 million, a 357% increase YoY, driven by ZORYVE® cream. FDA approval for ZORYVE® foam, 0.3%, for seborrheic dermatitis. PDUFA action date for roflumilast cream, 0.15%, in July 2024. Strong financial position supporting new launches and pipeline development. R&D expenses decreased by 39% in 2023. Company optimistic about 2024 potential.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.7%
Tags
earnings

FAQ

What is the current stock price of Arcutis Biotherapeutics (ARQT)?

The current stock price of Arcutis Biotherapeutics (ARQT) is $14.99 as of December 20, 2024.

What is the market cap of Arcutis Biotherapeutics (ARQT)?

The market cap of Arcutis Biotherapeutics (ARQT) is approximately 1.8B.

What does Arcutis Biotherapeutics, Inc. specialize in?

Arcutis specializes in developing and commercializing treatments for dermatological diseases, focusing on immune-mediated conditions.

What are the main products of Arcutis Biotherapeutics?

Arcutis' main products include ZORYVE (roflumilast) cream for plaque psoriasis and atopic dermatitis, and ZORYVE topical foam for seborrheic dermatitis and scalp psoriasis.

Where is Arcutis Biotherapeutics headquartered?

Arcutis Biotherapeutics is headquartered in Westlake Village, California.

When was Arcutis Biotherapeutics founded?

Arcutis Biotherapeutics was founded in 2016.

What is ZORYVE?

ZORYVE is a brand name for Arcutis' roflumilast cream and topical foam, used to treat plaque psoriasis, atopic dermatitis, seborrheic dermatitis, and scalp psoriasis.

What is the mechanism of action for ZORYVE?

ZORYVE utilizes roflumilast, a potent and selective phosphodiesterase-4 (PDE4) inhibitor, which helps reduce inflammation by regulating immune response mediators.

What are Arcutis' latest achievements?

Recent achievements include the successful launch of ZORYVE foam, strategic licensing agreements, and strong financial results from a public offering.

How is Arcutis ensuring long-term growth?

Arcutis ensures long-term growth through continuous innovation, expanding clinical programs, strategic collaborations, and robust financial management.

What are some of Arcutis' ongoing projects?

Ongoing projects include clinical programs for ARQ-252 for hand eczema, ARQ-255 for alopecia areata, and additional studies for topical roflumilast formulations.

Where can I get more information about Arcutis Biotherapeutics?

For more information, visit Arcutis' official website at www.arcutis.com or follow them on LinkedIn, Facebook, Instagram, and X.

Stock ARQT logo
Arcutis Biotherapeutics, Inc.

Nasdaq:ARQT

ARQT Rankings

#2039 Ranked by Market Cap
N/A Ranked by Dividends

ARQT Stock Data

1.80B
103.96M
2.15%
113.6%
21.37%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
WESTLAKE VILLAGE